According to results from the phase III INTRIGUE trial, ripretinib is not superior to sunitinib as a second-line tyrosine kinase inhibitor for patients with gastrointestinal stromal tumors in terms of progression-free survival. However, ripretinib had a better safety profile and induced fewer grade 3–4 toxicities, including hypertension.

You do not currently have access to this content.